• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study.

作者信息

Kozera Emily, Flora Akshay, Frew John W

机构信息

Department of Dermatology, Liverpool Hospital, Sydney, Australia; Laboratory of Translational Cutaneous Medicine, Ingham Institute, Sydney, Australia.

Department of Dermatology, Liverpool Hospital, Sydney, Australia; Laboratory of Translational Cutaneous Medicine, Ingham Institute, Sydney, Australia; University of New South Wales, Sydney, Australia.

出版信息

J Am Acad Dermatol. 2022 Dec;87(6):1440-1442. doi: 10.1016/j.jaad.2022.07.047. Epub 2022 Aug 4.

DOI:10.1016/j.jaad.2022.07.047
PMID:35934210
Abstract
摘要

相似文献

1
Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study.JAK激酶抑制剂乌帕替尼治疗化脓性汗腺炎的真实世界安全性及临床反应：一项回顾性队列研究
J Am Acad Dermatol. 2022 Dec;87(6):1440-1442. doi: 10.1016/j.jaad.2022.07.047. Epub 2022 Aug 4.
2
A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment.一项关于 Janus 激酶抑制剂和脾酪氨酸激酶抑制剂治疗化脓性汗腺炎的系统评价。
Int Immunopharmacol. 2024 Jan 25;127:111435. doi: 10.1016/j.intimp.2023.111435. Epub 2023 Dec 26.
3
Off-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases.Janus 激酶抑制剂在炎症性皮肤疾病中的超适应证使用。
J Drugs Dermatol. 2023 Dec 1;22(12):1183-1190. doi: 10.36849/JDD.7500.
4
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature.化脓性汗腺炎和 JAK 抑制剂：已发表文献综述。
Medicina (Kaunas). 2023 Apr 20;59(4):801. doi: 10.3390/medicina59040801.
5
Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib.病例报告：用乌帕替尼治疗伴有免疫介导合并症的类银屑病样湿疹。
Front Immunol. 2024 Aug 5;15:1432233. doi: 10.3389/fimmu.2024.1432233. eCollection 2024.
6
Management of Hidradenitis Suppurativa Using Janus Kinase Inhibitors: An Evidence-Based Review.使用 Janus 激酶抑制剂治疗化脓性汗腺炎：一项基于证据的综述。
J Cutan Med Surg. 2023 Nov;27(6):665-667. doi: 10.1177/12034754231211794. Epub 2023 Nov 10.
7
Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study.接受乌帕替尼治疗的中度至重度特应性皮炎患者中JAK抑制剂相关痤疮的临床结局与管理：一项多中心回顾性研究
J Am Acad Dermatol. 2024 May;90(5):1031-1034. doi: 10.1016/j.jaad.2024.01.004. Epub 2024 Jan 9.
8
Upadacitinib (Rinvoq) - a new JAK inhibitor for rheumatoid arthritis.乌帕替尼（瑞福）——一种用于治疗类风湿性关节炎的新型JAK抑制剂。
Med Lett Drugs Ther. 2019 Nov 18;61(1585):183-185.
9
Upadacitinib treatment associated with varicella zoster infection complicated by haemophagocytic lymphohistiocytosis in a patient with severe hidradenitis suppurativa.在一名重度化脓性汗腺炎患者中，乌帕替尼治疗与水痘带状疱疹感染相关，并并发噬血细胞性淋巴组织细胞增生症。
J Eur Acad Dermatol Venereol. 2024 Feb;38(2):e139-e141. doi: 10.1111/jdv.19483. Epub 2023 Sep 13.
10
Rapid Attenuation of B-Cell and IFN-γ-Associated Chemokines in Clinical Responders to Jak Inhibition with Upadacitinib in Hidradenitis Suppurativa.在化脓性汗腺炎中使用乌帕替尼抑制Jak的临床反应者中B细胞和IFN-γ相关趋化因子的快速衰减
J Invest Dermatol. 2024 Feb;144(2):416-419.e5. doi: 10.1016/j.jid.2023.07.023. Epub 2023 Aug 25.

引用本文的文献

1
A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment.一项关于肿瘤坏死因子-α阻滞剂、抗白细胞介素和小分子抑制剂用于治疗头皮蜂窝织炎的系统评价。
Orphanet J Rare Dis. 2025 May 18;20(1):236. doi: 10.1186/s13023-025-03720-5.
2
Dual immunomodulator therapy with adalimumab and upadacitinib to treat recalcitrant hidradenitis suppurativa.阿达木单抗和乌帕替尼联合免疫调节剂疗法治疗顽固性化脓性汗腺炎。
JAAD Case Rep. 2024 Dec 16;56:74-76. doi: 10.1016/j.jdcr.2024.12.008. eCollection 2025 Feb.
3
European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.
欧洲化脓性汗腺炎/反向性痤疮S2k指南第2部分：治疗
J Eur Acad Dermatol Venereol. 2025 May;39(5):899-941. doi: 10.1111/jdv.20472. Epub 2024 Dec 19.
4
Hidradenitis Suppurativa: A Review of the Biologic and Small Molecule Immunomodulatory Treatments.化脓性汗腺炎：生物制剂和小分子免疫调节治疗综述
J Cutan Med Surg. 2025 Jan-Feb;29(1):NP1-NP20. doi: 10.1177/12034754241300292. Epub 2024 Nov 27.
5
Australasian hidradenitis suppurativa management guidelines.澳大利亚化脓性汗腺炎管理指南。
Australas J Dermatol. 2025 Mar;66(2):75-89. doi: 10.1111/ajd.14388. Epub 2024 Nov 22.
6
Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose?阻断特应性皮炎中的白细胞介素-4/白细胞介素-13轴与Janus激酶/信号转导及转录激活因子途径：我们该如何选择？
J Pers Med. 2024 Jul 22;14(7):775. doi: 10.3390/jpm14070775.
7
Rethinking Hidradenitis Suppurativa Management: Insights into Bacterial Interactions and Treatment Evolution.重新思考化脓性汗腺炎的管理：对细菌相互作用和治疗进展的见解
Antibiotics (Basel). 2024 Mar 17;13(3):268. doi: 10.3390/antibiotics13030268.
8
Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib.乌帕替尼试验后头皮顽固性蜂窝织炎的改善
Cureus. 2024 Jan 16;16(1):e52377. doi: 10.7759/cureus.52377. eCollection 2024 Jan.
9
Local and Sustained Baricitinib Delivery to the Skin through Injectable Hydrogels Containing Reversible Thioimidate Adducts.通过含有可逆硫代亚胺键加合物的可注射水凝胶实现皮肤的局部和持续巴利昔替尼递药。
Adv Healthc Mater. 2024 May;13(12):e2303256. doi: 10.1002/adhm.202303256. Epub 2024 Jan 26.
10
New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review.坏疽性脓皮病和化脓性汗腺炎的新治疗方法：综述。
J Dermatol. 2024 Feb;51(2):172-179. doi: 10.1111/1346-8138.17031. Epub 2023 Nov 27.